Baiyunshan subsidiary gets drug specification approval
Guangzhou Baiyunshan Pharmaceutical Holdings announced its subsidiary Guangzhou Baiyunshan Chenliji Pharmaceutical Factory received approval from the National Medical Products Administration for a supplemental application for Qianjin Baoyun Pill.
The approval allows for an additional "small honey pill" specification for the blood-nurturing and miscarriage prevention product. The new specification aims to improve patient convenience and market competitiveness.
The subsidiary invested approximately 716,000 yuan in research and development for this project, with sales revenue reaching 1.47 million yuan in 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Guangzhou Baiyunshan Pharmaceutical Holdings publishes news
Free account required • Unsubscribe anytime